Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 17, Issue 3, Pages 349-359Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.17.3.349
Keywords
adult-onset Still's disease; anakinra; autoinflammatory syndromes; IL-1Ra; juvenile idiopathic arthritis; rheumatoid arthritis
Categories
Ask authors/readers for more resources
Background: IL-1 receptor antagonist (IL-1Ra) is a naturally occurring IL-1Rl-binding molecule that blocks the biologic effects of the proinflammatory cytokine IL-1. A recombinant form of human IL-1Ra, anakinra (Kineret), has been approved for use in rheumatology initially to manage rheumatoid arthritis (RA) patients that are refractory to more conventional forms of treatment. Objective: This review summarizes the experience with anakinra in the treatment of patients with rheumatic diseases emphasizing its beneficial effects in novel applications. Methods: English-language trials of anakinra were searched using MEDLINE and abstracts from rheumatology scientific meetings. Results/conclusions: In the treatment of patients with RA anakinra is effective but inferior to TNF-alpha blocking agents. Over the last few years it has become increasingly evident that anakinra is highly effective and safe in patients with systemic-onset juvenile idiopathic arthritis, adult-onset Still's disease, hereditary autoinflammatory syndromes, Schnitzler's syndrome and recently in gouty attacks.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available